Literature DB >> 21865412

Age at onset as a determinant of presenting phenotype and initial relapse recovery in multiple sclerosis.

M Cossburn1, G Ingram, C Hirst, Y Ben-Shlomo, T P Pickersgill, N P Robertson.   

Abstract

BACKGROUND: Age at onset modifies prognosis in multiple sclerosis (MS) and may also exert an effect on the characteristics of disease ignition. Understanding how age influences presentation informs disease management and may allow differentiation of distinct clinical sub-groups.
OBJECTIVES: To determine the nature of age-specific presentations of relapsing-remitting MS (RRMS) with respect to onset symptoms, gender ratios and index event outcomes.
METHODS: In a prospective, population-based sample of 1424 patients in South-East Wales we examined associations between age at onset, clinical features and outcome of the onset event, making specific comparisons between paediatric, adolescent and late-onset MS.
RESULTS: Age at onset varied significantly between sexes (Male 31.2, Female 29.3, p = 0.002), 0.7% had paediatric onset, 2.7% adolescent onset and 2.8% late-onset MS (>50 years). Optic neuritis was common in younger patients and declined after age 30. Lower limb motor, facial sensory, sexual and sphincteric symptoms rose with age independent of sex and disease course. F:M ratios were highest <16 years of age and declined with increasing age, with a male excess in those over 50. Probability of complete recovery from index event declined with age from 87.4% in the youngest group to 68% in the eldest (p = 0.009).
CONCLUSIONS: Age at disease onset in RRMS exerts a significant effect on gender ratios and presenting phenotype, and allows identification of specific clinical sub-groups. In addition, ability to recover from initial relapse declines with age, suggesting accumulation of disability in MS is an age-dependent response to relapse.

Entities:  

Mesh:

Year:  2011        PMID: 21865412     DOI: 10.1177/1352458511417479

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  26 in total

1.  Tumor necrosis factor alpha (TNF-α) and its soluble receptors are associated with disability, disability progression and clinical forms of multiple sclerosis.

Authors:  Claudia Mara Ribeiro; Sayonara Rangel Oliveira; Daniela Frizon Alfieri; Tamires Flauzino; Damacio Ramón Kaimen-Maciel; Andréa Name Colado Simão; Michael Maes; Edna Maria Vissoci Reiche
Journal:  Inflamm Res       Date:  2019-09-26       Impact factor: 4.575

2.  Ovarian aging is associated with gray matter volume and disability in women with MS.

Authors:  Jennifer S Graves; Roland G Henry; Bruce A C Cree; Geralyn Lambert-Messerlian; Ruth M Greenblatt; Emmanuelle Waubant; Marcelle I Cedars; Alyssa Zhu; Peter Bacchetti; Stephen L Hauser; Jorge R Oksenberg
Journal:  Neurology       Date:  2017-12-22       Impact factor: 9.910

3.  Predicting onset of secondary-progressive multiple sclerosis using genetic and non-genetic factors.

Authors:  Elina Misicka; Corriene Sept; Farren B S Briggs
Journal:  J Neurol       Date:  2020-04-24       Impact factor: 4.849

4.  Clinical-radiological-pathological spectrum of central nervous system-idiopathic inflammatory demyelinating disease in the elderly.

Authors:  W Oliver Tobin; Chiara Costanzi; Yong Guo; Joseph E Parisi; Stephen D Weigand; Claudia F Lucchinetti
Journal:  Mult Scler       Date:  2016-10-19       Impact factor: 6.312

5.  Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis.

Authors:  Martina Novotna; M Mateo Paz Soldán; Nuhad Abou Zeid; Nilufer Kale; Melih Tutuncu; Daniel J Crusan; Elizabeth J Atkinson; Aksel Siva; B Mark Keegan; Istvan Pirko; Sean J Pittock; Claudia F Lucchinetti; John H Noseworthy; Brian G Weinshenker; Moses Rodriguez; Orhun H Kantarci
Journal:  Neurology       Date:  2015-07-24       Impact factor: 9.910

Review 6.  Biological determinants impact the neurovascular toxicity of nicotine and tobacco smoke: A pharmacokinetic and pharmacodynamics perspective.

Authors:  Sabrina Rahman Archie; Sejal Sharma; Elizabeth Burks; Thomas Abbruscato
Journal:  Neurotoxicology       Date:  2022-02-09       Impact factor: 4.294

7.  Genetic, Immune-Inflammatory, and Oxidative Stress Biomarkers as Predictors for Disability and Disease Progression in Multiple Sclerosis.

Authors:  Ana Paula Kallaur; Edna Maria Vissoci Reiche; Sayonara Rangel Oliveira; Andrea Name Colado Simão; Wildea Lice de Carvalho Jennings Pereira; Daniela Frizon Alfieri; Tamires Flauzino; Caio de Meleck Proença; Marcell Alysson Batisti Lozovoy; Damacio Ramón Kaimen-Maciel; Michael Maes
Journal:  Mol Neurobiol       Date:  2016-01-05       Impact factor: 5.590

Review 8.  Genetic, Epigenetic, and Environmental Factors Influencing Neurovisceral Integration of Cardiovascular Modulation: Focus on Multiple Sclerosis.

Authors:  Zohara Sternberg
Journal:  Neuromolecular Med       Date:  2015-10-26       Impact factor: 3.843

Review 9.  Age-related small vessel disease: a potential contributor to neurodegeneration in multiple sclerosis.

Authors:  Ruth Geraldes; Margaret M Esiri; Gabriele C DeLuca; Jacqueline Palace
Journal:  Brain Pathol       Date:  2017-03-12       Impact factor: 6.508

10.  The DNA copy number of human endogenous retrovirus-W (MSRV-type) is increased in multiple sclerosis patients and is influenced by gender and disease severity.

Authors:  Marta Garcia-Montojo; María Dominguez-Mozo; Ana Arias-Leal; Ángel Garcia-Martinez; Virginia De las Heras; Ignacio Casanova; Raphaël Faucard; Nadège Gehin; Alexandra Madeira; Rafael Arroyo; François Curtin; Roberto Alvarez-Lafuente; Hervé Perron
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.